These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 34779234)

  • 41. Comparison of Ticagrelor Versus Prasugrel for Inflammation, Vascular Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Requiring Coronary Stenting: A Prospective, Randomized, Crossover Trial.
    Jeong HS; Hong SJ; Cho SA; Kim JH; Cho JY; Lee SH; Joo HJ; Park JH; Yu CW; Lim DS
    JACC Cardiovasc Interv; 2017 Aug; 10(16):1646-1658. PubMed ID: 28838475
    [TBL] [Abstract][Full Text] [Related]  

  • 42. "Real-World" Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States.
    Larmore C; Effron MB; Molife C; DeKoven M; Zhu Y; Lu J; Karkare S; Lieu HD; Lee WC; Vetrovec GW
    Catheter Cardiovasc Interv; 2016 Oct; 88(4):535-544. PubMed ID: 26577386
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of Reduced-Dose Prasugrel and Standard-Dose Clopidogrel in Elderly Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Revascularization.
    Savonitto S; Ferri LA; Piatti L; Grosseto D; Piovaccari G; Morici N; Bossi I; Sganzerla P; Tortorella G; Cacucci M; Ferrario M; Murena E; Sibilio G; Tondi S; Toso A; Bongioanni S; Ravera A; Corrada E; Mariani M; Di Ascenzo L; Petronio AS; Cavallini C; Vitrella G; Rogacka R; Antonicelli R; Cesana BM; De Luca L; Ottani F; De Luca G; Piscione F; Moffa N; De Servi S;
    Circulation; 2018 Jun; 137(23):2435-2445. PubMed ID: 29459361
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative effectiveness and safety of antiplatelet drugs in patients with diabetes mellitus and acute coronary syndrome.
    Spoendlin J; Gagne JJ; Lewey JJ; Patorno E; Schneeweiss S; Desai RJ
    Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1361-1370. PubMed ID: 30379372
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative Effectiveness and Safety of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome: A Retrospective Cohort Analysis.
    Dawwas GK; Dietrich E; Winchester DE; Winterstein AG; Segal R; Park H
    Pharmacotherapy; 2019 Sep; 39(9):912-920. PubMed ID: 31332815
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
    Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
    Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
    Andell P; James SK; Cannon CP; Cyr DD; Himmelmann A; Husted S; Keltai M; Koul S; Santoso A; Steg PG; Storey RF; Wallentin L; Erlinge D;
    J Am Heart Assoc; 2015 Oct; 4(10):e002490. PubMed ID: 26452988
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype: A POPular Genetics Subanalysis.
    Claassens DMF; Bergmeijer TO; Vos GJA; Hermanides RS; van 't Hof AWJ; van der Harst P; Barbato E; Morisco C; Tjon Joe Gin RM; Asselbergs FW; Mosterd A; Herrman JR; Dewilde WJM; Janssen PWA; Kelder JC; Mahmoodi BK; Deneer VHM; Ten Berg JM
    Circ Cardiovasc Interv; 2021 Apr; 14(4):e009434. PubMed ID: 33722066
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment-Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention: The Randomized COMPARE CRUSH Trial.
    Vlachojannis GJ; Wilschut JM; Vogel RF; Lemmert ME; Delewi R; Diletti R; van der Waarden NWPL; Nuis RJ; Paradies V; Alexopoulos D; Zijlstra F; Montalescot G; Angiolillo DJ; Krucoff MW; Van Mieghem NM; Smits PC
    Circulation; 2020 Dec; 142(24):2316-2328. PubMed ID: 33315489
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and Safety of Clopidogrel, Prasugrel and Ticagrelor in ACS Patients Treated with PCI: A Propensity Score Analysis of the RENAMI and BleeMACS Registries.
    Peyracchia M; Saglietto A; Biolè C; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Liebetrau C; Manzano-Fernández S; Boccuzzi G; Henriques JPS; Wilton SB; Velicki L; Xanthopoulou I; Correia L; Rognoni A; Fabrizio U; Nuñez-Gil I; Montabone A; Taha S; Fujii T; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Kawaji T; Blanco PF; Garay A; Quadri G; Queija BC; Huczek Z; Paz RC; González-Juanatey JR; Fernández MC; Nie SP; D'Amico M; Pousa IM; Kawashiri MA; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Lopez-Cuenca A; Cequier A; Alexopoulos D; Iñiguez-Romo A; Grossomarra W; Usmiani T; Rinaldi M; D'Ascenzo F
    Am J Cardiovasc Drugs; 2020 Jun; 20(3):259-269. PubMed ID: 31586336
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Incidence and predictors of bleeding in ACS patients treated with PCI and prasugrel or ticagrelor: An analysis from the RENAMI registry.
    D'Ascenzo F; Grosso A; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Ali HH; Magnani G; Autelli M; Blanco PF; Garay A; Quadri G; Marra WG; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Raposeiras-Roubin S
    Int J Cardiol; 2018 Dec; 273():29-33. PubMed ID: 30228021
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of the effects of P2Y12 receptor antagonists on platelet function and clinical outcomes in patients undergoing Primary PCI: A substudy of the HEAT-PPCI trial.
    Shahzad A; Khanna V; Kemp I; Shaw M; Mars C; Cooper R; Wilson K; Curzen N; Stables RH
    EuroIntervention; 2018 Mar; 13(16):1931-1938. PubMed ID: 29336311
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
    J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study.
    Jin C; Kim MH; Bang J; Serebruany V
    Cardiology; 2017; 138(4):201-206. PubMed ID: 28810251
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and Efficacy in Prasugrel- Versus Ticagrelor-Treated Patients With ST-Elevation Myocardial Infarction.
    Dimitroulis D; Golabkesh M; Naguib D; Knoop B; Dannenberg L; Helten C; Pöhl M; Jung C; Kelm M; Zeus T; Polzin A
    J Cardiovasc Pharmacol; 2018 Oct; 72(4):186-190. PubMed ID: 29985284
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre-Specified Analysis of the GLOBAL LEADERS Trial.
    Vranckx P; Valgimigli M; Odutayo A; Serruys PW; Hamm C; Steg PG; Heg D; Mc Fadden EP; Onuma Y; Benit E; Janssens L; Diletti R; Ferrario M; Huber K; Räber L; Windecker S; Jüni P;
    J Am Heart Assoc; 2021 Sep; 10(18):e015560. PubMed ID: 34533034
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Holdt L; Felix SB; Parma R; Klopotowski M; Schwinger RHG; Rieber J; Huber K; Neumann FJ; Koltowski L; Mehilli J; Huczek Z; Massberg S;
    Lancet; 2017 Oct; 390(10104):1747-1757. PubMed ID: 28855078
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clopidogrel, prasugrel, and ticagrelor for all-comers with ST-segment elevation myocardial infarction.
    Jacobsen MR; Engstrøm T; Torp-Pedersen C; Gislason G; Glinge C; Butt JH; Fosbøl EL; Holmvang L; Pedersen F; Køber L; Jabbari R; Sørensen R
    Int J Cardiol; 2021 Nov; 342():15-22. PubMed ID: 34311012
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Head to head comparison of Prasugrel versus Ticagrelor in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized trials.
    Bundhun PK; Shi JX; Huang F
    BMC Pharmacol Toxicol; 2017 Dec; 18(1):80. PubMed ID: 29233189
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prasugrel vs. Ticagrelor for Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.
    Khan MS; Memon MM; Usman MS; Alnaimat S; Khan SU; Khan AR; Yamani N; Fugar S; Mookadam F; Krasuski RA; Doukky R
    Am J Cardiovasc Drugs; 2019 Oct; 19(5):465-476. PubMed ID: 30828769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.